Free Trial

GAMMA Investing LLC Boosts Holdings in Alkermes plc (NASDAQ:ALKS)

Alkermes logo with Medical background

GAMMA Investing LLC lifted its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 4,255.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 178,176 shares of the company's stock after purchasing an additional 174,085 shares during the quarter. GAMMA Investing LLC owned 0.11% of Alkermes worth $5,396,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. RTW Investments LP lifted its position in shares of Alkermes by 13.6% in the fourth quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock worth $217,363,000 after purchasing an additional 903,802 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Alkermes by 1.1% in the fourth quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company's stock worth $157,568,000 after purchasing an additional 57,697 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Alkermes by 6.5% in the fourth quarter. American Century Companies Inc. now owns 3,450,707 shares of the company's stock worth $99,242,000 after purchasing an additional 209,740 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Alkermes by 4.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company's stock worth $86,842,000 after purchasing an additional 128,701 shares in the last quarter. Finally, Avoro Capital Advisors LLC bought a new stake in Alkermes during the fourth quarter worth $70,462,000. Institutional investors own 95.21% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on ALKS. HC Wainwright reaffirmed a "neutral" rating on shares of Alkermes in a research report on Friday, May 2nd. UBS Group reaffirmed a "sector perform" rating on shares of Alkermes in a research report on Monday, April 28th. Cantor Fitzgerald raised shares of Alkermes to a "strong-buy" rating in a research report on Tuesday, May 13th. Needham & Company LLC started coverage on shares of Alkermes in a research report on Wednesday, May 28th. They set a "buy" rating and a $45.00 price target on the stock. Finally, Robert W. Baird increased their price objective on shares of Alkermes from $38.00 to $41.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.85.

View Our Latest Stock Report on Alkermes

Insider Activity at Alkermes

In other Alkermes news, SVP Christian Todd Nichols sold 3,333 shares of Alkermes stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $31.95, for a total transaction of $106,489.35. Following the transaction, the senior vice president now directly owns 89,542 shares of the company's stock, valued at approximately $2,860,866.90. This trade represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.40% of the stock is currently owned by insiders.

Alkermes Stock Performance

NASDAQ ALKS traded down $0.95 during trading on Friday, hitting $29.83. 2,207,105 shares of the company's stock traded hands, compared to its average volume of 1,734,585. The stock has a market capitalization of $4.92 billion, a price-to-earnings ratio of 13.75, a PEG ratio of 2.20 and a beta of 0.47. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $36.45. The business has a 50 day moving average of $29.63 and a 200-day moving average of $31.02.

Alkermes (NASDAQ:ALKS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The firm had revenue of $306.51 million during the quarter, compared to the consensus estimate of $307.53 million. During the same quarter last year, the business posted $0.43 earnings per share. Alkermes's revenue was down 12.6% compared to the same quarter last year. On average, analysts expect that Alkermes plc will post 1.31 EPS for the current year.

Alkermes Profile

(Free Report)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

Featured Stories

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Should You Invest $1,000 in Alkermes Right Now?

Before you consider Alkermes, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.

While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines